Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharming Group ( (PHAR) ) has provided an update.
Pharming Group N.V. announced on April 16, 2026 that it will hold its 2026 Annual General Meeting of Shareholders on May 28, 2026 at the Corpus Congress Centre in Oegstgeest, the Netherlands, with a live webcast available. The AGM agenda includes appointing KPMG N.V. as external auditor for 2026–2028, amending the remuneration policy for non-executive directors’ fees, and renewing board authorizations to issue and repurchase shares, decisions that could influence Pharming’s governance, capital structure flexibility and oversight of its financial reporting.
These proposals position Pharming to maintain robust auditing arrangements and adjust director compensation in line with its strategic needs while preserving the ability to manage its equity base through new share issuance and buybacks. For shareholders and other stakeholders, the meeting will be a key forum to review the company’s governance framework and authorize tools that can support future financing, incentive schemes and balance sheet management.
The most recent analyst rating on (PHAR) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Pharming Group stock, see the PHAR Stock Forecast page.
Spark’s Take on PHAR Stock
According to Spark, TipRanks’ AI Analyst, PHAR is a Neutral.
The score is driven primarily by improving financial performance (return to profitability and stronger cash flow) and supportive technicals (price above key moving averages with positive momentum). These positives are offset by a very expensive valuation (extremely high P/E) and the risk implied by recent TTM revenue contraction and thin net margins.
To see Spark’s full report on PHAR stock, click here.
More about Pharming Group
Pharming Group N.V. is a global biopharmaceutical company focused on developing and commercializing innovative medicines, including small molecules and biologics, for patients with rare, debilitating and life-threatening diseases. Headquartered in Leiden, the Netherlands, the company has a significant portion of its workforce based in the U.S. and is listed on Euronext Amsterdam and Nasdaq.
Average Trading Volume: 27,313
Technical Sentiment Signal: Strong Buy
Current Market Cap: $1.27B
For detailed information about PHAR stock, go to TipRanks’ Stock Analysis page.